GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SenzaGen AB (OSTO:SENZA) » Definitions » Capital Expenditure

SenzaGen AB (OSTO:SENZA) Capital Expenditure : kr-5.11 Mil (TTM As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is SenzaGen AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

SenzaGen AB's cash flow for capital expenditures for the three months ended in Mar. 2025 was kr-0.97 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was kr-5.11 Mil.

SenzaGen AB Capital Expenditure Historical Data

The historical data trend for SenzaGen AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SenzaGen AB Capital Expenditure Chart

SenzaGen AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.45 -2.67 -2.59 -3.81 -4.53

SenzaGen AB Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -1.07 -0.50 -2.57 -0.97

SenzaGen AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SenzaGen AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SenzaGen AB (OSTO:SENZA) » Definitions » Capital Expenditure
Comparable Companies
OSTO:AROC OSTO:IMMNOV NGM:LUMITO XSAT:GEAN NGM:ATANA NGM:LEVBIO OSTO:PROGEN XSAT:SPERM TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH DGX
Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Building 401, Lund, SWE, 223 81
Website
https://www.senzagen.com
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.

SenzaGen AB Headlines

No Headlines